Cancer Chemother Pharmacol 2008, 61:415–21.PubMedCrossRef 25. Barlogie B, Corry PM, Drewinko B: In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum (II) and mitomycin C. Cancer Res 1980, 40:1165–8.PubMed 26. Eichholtz-Wirth H, Hietel B: Heat sensitization to cisplatin in two cell lines with different drug sensitivities. Int J buy MS-275 hyperthermia 1990, 6:47–55.PubMedCrossRef 27. Los G, Sminia P, Wondergem J, Mutsaers PH, Havemen J, ten Bokkel HD, et al.: Optimisation of intraperitoneal cisplatin therapy with regional hyperthermia in rats. Eur J Cancer
1991, 27:472–7.PubMedCrossRef 28. Meyn RE, Corry PM, Fletcher SE, Demetriades M: Thermal enhancement of DNA damage in mammalian cells treated with Evofosfamide datasheet cis-diamminedichloroplatinum (II). Cancer Res 1980, 40:1136–9.PubMed 29. Conti M, De GU, Tazzari V, Bezzi F, Baccini C: Clinical pharmacology of intraperitoneal cisplatin-based chemotherapy. J Chemother 2004,16(Suppl 5):23–5.PubMed 30. Los G, van Vugt MJ, Pinedo HM: Response of peritoneal solid tumours after intraperitoneal
chemohyperthermia treatment with cisplatin or carboplatin. Br J Blasticidin S manufacturer Cancer 1994, 69:235–41.PubMedCrossRef 31. Zeamari S, Floot B, van d, Stewart FA: Pharmacokinetics and pharmacodynamics of cisplatin after intraoperative hyperthermic intraperitoneal chemoperfusion (HIPEC). Anticancer Res 2003, 23:1643–8.PubMed 32. El-Kareh AW, Secomb TW: A theoretical model for intraperitoneal delivery of cisplatin and the effect of hyperthermia on drug penetration distance. Neoplasia 2004, 6:117–27.PubMedCrossRef 33. Ausmus PL, Wilke AV, Frazier DL: Effects of hyperthermia on blood flow and cis-diamminedichloroplatinum (II) pharmacokinetics in murine mammary adenocarcinomas. Cancer Res 1992,
52:4965–8.PubMed Authors’ contributions OF, FR and DD carried out the in vivo experiments. SL and HT carried out the in vitro experiments. BC participated in the design of the study and performed the statistical analysis. POD, FG and PR conceived the study, and participated in its design and coordination. All authors read and approved the final manuscript.”
“Background tetracosactide Immortalized and malignant tumor cells are characterized by unlimited cell proliferation and programmed cell death (apoptosis). It has been demonstrated that malignant transformation occurs when the telomerase in normal cell is activated [1, 2]. Telomerase activity is found in almost all malignant tumors . Human telomerase RNA (hTR) is associated with the activity of telomerase, immortalized cancer cells retain the highest level of hTR [4, 5]. In recent years, hammerhead ribozymes were used to inhibit the telomerase activity by targeting the template region of telomerase RNA in malignant tumors [6, 7]. Yet, there is no report about HDV ribozyme for inhibition of telomerase activity.